NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. (U.S.), ANNOUNCES DETAILS OF LACRIFILL® CANALICULAR GEL POSTER PRESENTATION AT SECO 2025

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

NordicPharma-SECO25

More Like This

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Continues Its Introduction of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, During American Academy of Ophthalmology (AAO) 2024

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), to Present Data on LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye, at the American Society of Cataract and Refractive Surgery Annual Meeting

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces the Launch of LACRIFILL® Canalicular Gel, a Novel Therapy for Dry Eye.

Nordic Pharma Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Completes Acquisition of Visant Medical to Launch Novel Therapy for Dry Eye Disease in the United States

Nordic Group B.V. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Appoints Renowned Oculoplastic Surgeon, John P. Fezza, MD to Its Medical Advisory Board

Nordic Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Announces Jai G. Parekh, MD, MBA as Chief Commercial Officer, Eye Care U.S.

Nordic Group B.V. Through Its Subsidiary Amring Pharmaceuticals Inc., Appoints Ophthalmology Innovator, Eric D. Donnenfeld, MD as Medical Advisory Board Chair

IMCAS 2024: Galderma to Present Latest Updates From Its Unparalleled Aesthetics Portfolio Reinforcing Its Leadership Position